Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicenter randomized controlled clinical trial
Description
CONCLUSIONS: Nafamostat exerts virus load-reducing effects in patients with early-onset COVID-19.